Vivo Capital LLC maintained its position in shares of Trevena, Inc. (NASDAQ:TRVN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,728,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Trevena makes up about 1.0% of Vivo Capital LLC’s holdings, making the stock its 16th largest position. Vivo Capital LLC’s holdings in Trevena were worth $3,974,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. American International Group Inc. increased its position in shares of Trevena by 7.1% in the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 1,816 shares during the last quarter. Bourgeon Capital Management LLC increased its position in shares of Trevena by 56.8% in the second quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 19,200 shares during the last quarter. Daiwa SB Investments Ltd. bought a new position in shares of Trevena during the first quarter worth approximately $126,000. SG Americas Securities LLC increased its position in shares of Trevena by 81.0% in the first quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 16,079 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Trevena by 30.1% in the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 14,880 shares during the last quarter. Hedge funds and other institutional investors own 64.40% of the company’s stock.

Trevena, Inc. (NASDAQ TRVN) opened at 2.41 on Friday. The company’s market cap is $143.87 million. Trevena, Inc. has a 1-year low of $2.15 and a 1-year high of $8.00. The stock has a 50 day moving average price of $2.55 and a 200 day moving average price of $3.63.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.35). Equities analysts forecast that Trevena, Inc. will post ($1.40) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Vivo Capital LLC Has $3,974,000 Stake in Trevena, Inc. (NASDAQ:TRVN)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/13/vivo-capital-llc-has-3974000-stake-in-trevena-inc-nasdaqtrvn.html.

A number of research analysts recently commented on TRVN shares. Needham & Company LLC upped their price objective on Trevena from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, May 15th. HC Wainwright restated a “buy” rating on shares of Trevena in a research note on Monday, May 8th. Roth Capital set a $9.00 price objective on Trevena and gave the stock a “buy” rating in a research note on Saturday, May 6th. Oppenheimer Holdings, Inc. set a $10.00 price objective on Trevena and gave the stock a “buy” rating in a research note on Thursday, May 4th. Finally, Aegis restated a “buy” rating and set a $14.00 price objective on shares of Trevena in a research note on Monday, April 17th. One investment analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. Trevena has an average rating of “Buy” and a consensus price target of $10.56.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding TRVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevena, Inc. (NASDAQ:TRVN).

Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.